SLSSELLAS Life Sciences Group,...

Nasdaq sellaslifesciences.com


$ 1.32 $ -0.01 (-0.75 %)    

Friday, 13-Sep-2024 15:59:51 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 1.32
$ 1.31 x 1,020
$ 1.32 x 998
-- - --
$ 0.50 - $ 1.90
435,985
na
84.92M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sellas-life-sciences-gr-q2-eps-013-beats-017-estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate o...

 sellas-receives-ema-orphan-drug-designation-for-sls009-for-treatment-of-peripheral-t-cell-lymphomas

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

 sellas-announces-us-fda-rare-pediatric-disease-designation-granted-to-sls009-for-the-treatment-of-pediatric-acute-myeloid-leukemia

- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prog...

 sellas-life-sciences-announced-review-of-ongoing-phase-3-regal-clinical-trial-of-galinpepimut-s-in-acute-myeloid-leukemia-by-idmc

–  The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications ––...

 sellas-life-sciences-completes-enrollment-and-reports-positive-initial-data-from-phase-2a-trial-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia

- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - Overall Response Rate (ORR) of 3...

 sellas-life-sciences-gr-q1-2024-adj-eps-021-misses-016-estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...

 sellas-life-sciences-announces-recommendation-of-independent-data-monitoring-committee-following-completion-of-enrollment-in-regal-phase-3-study

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of P...

 sellas-life-sciences-gr-q4-eps-025-misses-021-estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate...

 sellas-announces-topline-data-from-phase-2a-study-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia-and-provides-steering-committee-update-on-phase-3-regal-study

Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Schedu...

 dow-falls-over-200-points-adobe-shares-plunge

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded...

 why-jabil-shares-are-trading-lower-by-over-14-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter resu...

 crude-oil-edges-lower-us-consumer-sentiment-falls-in-march

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded do...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION